Hormone therapy is used for several different purposes, from managing menopause symptoms to treating cancer to gender-affirming care, and the side effects vary significantly depending on which type you’re on. Some side effects are temporary and settle within weeks, while others require ongoing monitoring. Here’s what to expect across the major types of hormone therapy.
Menopause Hormone Therapy
The most common side effects of menopausal hormone therapy (MHT) are irregular vaginal bleeding, breast tenderness, and mood swings. Less common effects include bloating, headaches, skin discoloration, and increased breast density that can make mammograms harder to read. Most of these are worst in the first few months. Breast tenderness typically resolves within two to three months, headaches within a few weeks, and fluid retention usually improves after one to two months.
The more serious risks depend heavily on how the hormones are delivered. Oral estrogen, which passes through the liver before entering your bloodstream, carries a roughly 70% higher risk of blood clots compared to women who’ve never used hormone therapy. Transdermal estrogen (patches or gels) largely avoids this problem because it bypasses the liver. A large French cohort study found no significant increase in clot risk with transdermal estrogen. For this reason, current guidelines recommend patches or gels over pills for women who smoke, have high blood pressure, are overweight, or have other cardiovascular risk factors.
The type of progestogen matters too. Some synthetic progestogens nearly double the clot risk, while micronized progesterone (a form closer to what the body naturally produces) showed no increased risk in the same study. If you need combined therapy, the combination of transdermal estrogen with micronized progesterone appears to carry the lowest cardiovascular risk.
Mood and Depression Risk
A large Danish study found that women who started systemic hormone therapy before or during menopause had a 50% higher risk of being diagnosed with depression, particularly in the first year after starting treatment. The risk was elevated for both estrogen-only and combined estrogen-progestogen formulas. Interestingly, locally applied estrogen (vaginal creams or rings) showed no increased depression risk, and women who started local therapy after age 54 actually had a 20% lower risk of depression. This suggests the mood effects are tied to systemic hormone levels, not estrogen exposure in general.
Timing and Long-Term Use
Starting MHT before age 60 or within 10 years of menopause carries a very different risk profile than starting later. Women who begin in this “window” don’t appear to face increased stroke risk, and some research suggests a 32% reduction in coronary artery disease risk. Standard-dose therapy also reduces fractures of the hip, spine, and other sites, even in women without osteoporosis.
For women with premature ovarian insufficiency (menopause before 40), therapy is recommended until the typical age of natural menopause to protect bone and heart health. For others, there’s no hard cutoff at 60 or 65. Continuing therapy is reasonable for healthy women with persistent symptoms and low cardiovascular and breast cancer risk, though periodic reassessment is advised.
Breast Cancer Hormone Therapy
Hormone therapy for breast cancer works in the opposite direction from menopausal therapy. Instead of adding hormones, it blocks or lowers estrogen to starve hormone-receptor-positive tumors. The two main categories are selective estrogen receptor modulators (like tamoxifen) and aromatase inhibitors, and their side effect profiles are quite different.
Tamoxifen blocks estrogen in breast tissue but acts like estrogen in the uterus, which means it can cause endometrial thickening, uterine polyps, fibroids, and in rare cases, endometrial cancer. It also commonly triggers hot flashes and vaginal dryness.
Aromatase inhibitors, which lower estrogen levels throughout the body, are associated with bone density loss, joint pain and stiffness, and sexual dysfunction. The joint symptoms can be significant enough that some women consider stopping treatment. Because these drugs accelerate bone thinning, bone density monitoring becomes important during treatment.
Prostate Cancer Hormone Therapy
Androgen deprivation therapy (ADT) for prostate cancer suppresses testosterone, and the metabolic consequences are substantial. In a prospective study of men on ADT for one year, body weight increased about 2%, body fat increased roughly 9 to 11%, and lean muscle mass dropped 3 to 4%. These changes begin within months and continue over time.
The metabolic effects go beyond body composition. Insulin sensitivity drops by about 13% within just 12 weeks of treatment, increasing the risk of developing diabetes. Hot flashes are extremely common, often more frequent and intense than what women experience during menopause. Fatigue, reduced libido, erectile dysfunction, and bone thinning are also expected effects that persist for as long as treatment continues.
Feminizing Hormone Therapy
For transgender women and transfeminine individuals taking estrogen, the side effect profile shares some overlap with menopausal hormone therapy but has its own distinct pattern. Blood clot risk is the primary cardiovascular concern. One retrospective study of 676 transgender women on oral estradiol found a clot rate of 0.15% over an average of about two years, though cardiovascular and thromboembolic events collectively accounted for 36% of reported adverse reactions in a French pharmacovigilance database. As with menopausal therapy, transdermal estrogen appears to carry lower clot risk than oral formulations, and guidelines recommend it for anyone over 40 or with cardiovascular risk factors.
Early side effects like mood swings, headaches, nausea, and fatigue typically stabilize within two to four weeks. Breast tenderness begins within weeks and can continue for two to three years as breast development progresses. Skin changes (oiliness or dryness) usually settle within three to six months. Libido changes are common and generally stabilize in that same window. Fat redistribution becomes noticeable around three to six months and continues gradually.
Masculinizing Hormone Therapy
For transgender men and transmasculine individuals taking testosterone, the most clinically important side effect is erythrocytosis, a condition where the body produces too many red blood cells, thickening the blood and raising the risk of clots. In a large cohort study, 11% of trans men on testosterone developed elevated red blood cell levels. The biggest jump happens in the first year, with levels rising significantly from baseline, but the probability of developing erythrocytosis continues to climb over time: 10% after one year, 38% after ten years. Smoking more than doubles the risk, and injectable testosterone carries higher risk than gel formulations.
Acne and oily skin are very common, typically peaking around six months and improving by the one-year mark. Increased muscle mass develops gradually over six to 24 months. Voice deepening may begin within months but can take one to two years to fully develop. Male-pattern hair growth starts within three to six months and continues developing over years. These are desired effects for most people on masculinizing therapy, but they’re worth understanding as permanent changes that won’t reverse if treatment stops.
How Delivery Method Affects Side Effects
Across nearly all forms of hormone therapy, how the hormones enter your body makes a meaningful difference. Oral hormones pass through the liver first (called first-pass metabolism), which triggers changes in clotting factors, triglycerides, and inflammatory markers. Transdermal delivery through patches or gels skips the liver entirely, which is why it consistently shows lower rates of blood clots and has less impact on blood pressure and cholesterol.
Vaginal or locally applied hormones deliver estrogen only to nearby tissue with minimal absorption into the bloodstream. This is why local estrogen therapy doesn’t carry the same clot, stroke, or depression risks as systemic therapy. For women who only need relief from vaginal dryness or urinary symptoms, local application provides benefits without most of the systemic side effects.
No studies have directly compared patches to gels head-to-head, so the choice between those two transdermal options comes down to personal preference, skin sensitivity, and cost rather than a clear safety difference.
What Monitoring Looks Like
Regular blood work is part of every long-term hormone therapy regimen, though what’s being checked varies by type. For masculinizing therapy, red blood cell counts need monitoring at least annually, with more frequent checks in the first year when levels rise fastest. For menopausal therapy, mammograms remain important since increased breast density can obscure findings. For prostate cancer ADT, blood sugar and bone density scans become part of routine follow-up given the metabolic and skeletal effects.
Many side effects are manageable through dose adjustments, switching delivery methods, or changing the specific hormone formulation. Joint pain from aromatase inhibitors, clot risk from oral estrogen, and mood changes from systemic menopausal therapy have all been shown to improve with these kinds of modifications.